Tidepool Loop receives FDA clearance
The future of diabetes management has arrived! Tidepool Loop, the first fully interoperable automated insulin dosing app, has recently received FDA clearance. This groundbreaking development marks a major milestone in diabetes care, giving people with diabetes more control over their health and wellness.
Tidepool Loop is an innovative, patient-led initiative that provides users with an automated insulin dosing system, allowing them to manage their diabetes without having to manually adjust insulin doses. The app allows users to monitor their glucose levels in real-time and adjust insulin levels accordingly. It also gives users access to a library of personalized settings, which they can use to customize their insulin dosing to suit their individual needs.
The app is designed to be user-friendly, with a simple, intuitive interface that makes it easy to track data, view insights, and adjust settings. It also has built-in safety features like low-glucose suspend, which automatically suspends insulin delivery when a user’s glucose levels reach a certain threshold. This ensures that users are always getting the right amount of insulin, while also providing peace of mind.
Tidepool Loop is an invaluable tool for people with diabetes, providing them with greater access to health care and more control over their health and wellness. The app is also a great resource for healthcare professionals, giving them access to real-time patient data and allowing them to make more informed decisions when it comes to diabetes management.
The FDA clearance of Tidepool Loop is a groundbreaking development for diabetes care, and it will undoubtedly have a profound impact on the lives of people with diabetes. This app is a major step forward in diabetes management, providing users with greater freedom and control over their health and wellness. We’re excited to see how this innovative technology will continue to shape the future of diabetes management in the years to come.
To learn much more listen to this Juicebox Podcast interview with President, CEO and Founder of Tidepool, Howard Look.
Contour Next One App
The Contour Diabetes app now integrates with Apple Health. Once you enabled the feature, data from the Contour app will be available in the Blood Glucose area of your iOS Health app.
This is the meter that Omnipod users will be receiving when the DASH PDM is released sometime in the first quarter of 2019. Arden is using it now and we are finding the accuracy to be terrific!
Omnipod® Horizon™ System Significantly Improves Glycemic Control in Patients with Type 1 Diabetes
Good news for the future from Omnipod!
BILLERICA, Mass.--(BUSINESS WIRE)--Jun. 24, 2018-- Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Glucose Control System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando.
The study demonstrated that the Omnipod Horizon System performed well and was safe for over five days of use in adults, adolescents, and children with type 1 diabetes.
“In the era of personalized medicine, Insulet is committed to bringing our innovative technology to the global diabetes community and our clinical data give us confidence that the Omnipod Horizon System will be a significant advancement in diabetes management.”
The study was conducted in a supervised hotel setting under free-living conditions with unrestricted meals and moderate-intensity exercise and included patients who use multiple daily injections or traditional tubed insulin pumps as their standard therapy. Study participants spent significantly less time in hypoglycemia, more time in the target glucose range and had better overnight glycemic control compared to their standard therapy. The investigational device includes features that allowed study participants to customize their diabetes management by adjusting their target blood glucose levels and insulin delivery.
“We recognize that everyone’s treatment needs are different, and the Omnipod Horizon System provides individualized diabetes management to address real world challenges,” said Dr. Jennifer L. Sherr, MD, PhD, of Yale University School of Medicine. “One of the important features is the ability for users to tailor the system for exercise and high fat meals to maintain good glycemic control.”
During the study, glucose control was maintained in the target range (70 to 180 mg/dL) between 69% and 79% of the time overall, and between 74% and 85% of the time during the overnight period, across all age groups. Hypoglycemia was very low overnight, ranging from 0.7% and 1.3% of the time, across age groups.
“In the era of personalized medicine, Insulet is committed to bringing our innovative technology to the global diabetes community and our clinical data give us confidence that the Omnipod Horizon System will be a significant advancement in diabetes management,” said Dr. Trang Ly, Senior Vice President and Medical Director. “We are very pleased that for the second consecutive year, Omnipod Horizon System research was highlighted in the official ADA Press Program based upon its overall excellence in furthering research and advancing treatment for people with diabetes.”
Daylight Savings Time
Don’t forget -- your microwave isn't the only clock that requires adjusting tonight.
The clocks in your meters, insulin pumps and CGMs need to ‘Spring Forward’ as well… #diabetes #daylightsavingstime
Important: Some insulin pumps may not offer bolus calculations for a period of time after you make clock adjustments.
PHOTO: National Geographic - news.nationalgeographic.com
Photo of a man adjusting giant clocks. Peter Shugrue checks a clock at the Electric Time Company factory in Medfield, Massachusetts, on March 8, 2013.
Juicebox Podcast
Did Eli Lilly just get into the insulin pump game?
Dexcom said today that it inked a development deal with Eli Lilly to include its continuous glucose monitor in the insulin-maker’s connected delivery devices.
The pair plans to start clinical trials by the end of this year, adding that they hope to position the combination of their technologies as a comprehensive solution for people with diabetes.
“Lilly’s Connected Diabetes Ecosystem promises to drive a significant step forward in diabetes management. As technology converges in our industry, we believe that connected systems will become the standard of care over time,” Kevin Sayer, Dexcom president & CEO said in prepared remarks.
“By combining devices, drugs and technology, we can deliver solutions that adapt to each person’s unique needs in managing their diabetes while also providing compelling advancements for both physicians and payers.”
“The Connected Diabetes Ecosystem relies not only on Lilly’s core diabetes expertise, but also the strength of our key partners such as Dexcom,” Enrique Conterno, president of Lilly Diabetes and Lilly USA, added. “Dexcom will be an important collaborator in our mission to improve outcomes and reduce the daily burden for people with diabetes.”